Targeted Strategies for Today's Evolving Markets

MissionIR Blog

NanoViricides, Inc. (NNVC) Starts Presentation at 2015 Marcum MicroCap Conference

NanoViricides is a nano-biopharmaceutical company focused on discovering, developing and marketing therapeutics for the treatment of viral infections. The company is developing anti-flu drug candidates at pre-clinical and advanced pre-clinical stage.  These candidates include two FluCide drugs made up of NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Pathogenic Influenzas. For more information visit the company website at

The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in Marcum MicroCap. Bookmark the permalink.

Comments are closed.